Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Jem Headlands LLC

Neither a doctor nor a teaching hospital

Research payments

$30,246,795

711 payments

Through program year 2025, Jem Headlands LLC is reported as receiving $30,246,795 in research payments, across 711 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $3,791,614 203
2024 Research $4,924,181 117
2023 Research $5,599,640 118
2022 Research $7,706,293 163
2021 Research $6,496,800 84
2020 Research $1,728,268 26

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $15,126,376 48 payments
  2. Janssen Research & Development, LLC $5,386,183 262 payments
  3. AstraZeneca Pharmaceuticals LP $3,209,254 12 payments
  4. Pfizer Inc. $1,440,551 93 payments
  5. Moderna TX, Inc. $1,335,623 45 payments
  6. Eisai Inc. $937,802 25 payments
  7. Ucb SA $770,892 13 payments
  8. GlaxoSmithKline, LLC. $626,289 66 payments
  9. AbbVie, Inc. $418,256 56 payments
  10. AstraZeneca UK Limited $317,533 3 payments
Studies the money was for Research payments · program years 2020–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $5,963,666 5 payments
  2. A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults $3,538,383 78 payments
  3. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $2,481,172 6 payments
  4. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $2,046,031 2 payments
  5. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,746,351 2 payments
  6. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $1,134,018 1 payment
  7. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $1,081,738 4 payments
  8. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease $1,058,976 90 payments
  9. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $922,910 9 payments
  10. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $902,255 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record